Zobrazeno 1 - 10
of 24
pro vyhledávání: '"D. Bruce Sodee"'
Autor:
Edward Kim, Christopher C. Whalen, Rodney J. Ellis, D. Bruce Sodee, Pingfu Fu, John P. Spirnak, Martin I. Resnick, Deborah A. Kaminsky, Hang Zhou, Valdir C. Colussi
Publikováno v:
Brachytherapy. 6:149-156
Purpose To evaluate rectal morbidity after dose escalation to biologic target volumes identified by capromab pendetide (ProstaScint) single-photon emission tomography images coregistered with computed tomography (SPECT/CT). Methods and materials Two
Publikováno v:
Academic Radiology. 12:815-824
Rationale and Objectives Three-dimensional (3D) nonrigid image registration for potential applications in prostate cancer treatment and interventional magnetic resonance (iMRI) imaging–guided therapies were investigated. Materials and Methods An al
Publikováno v:
Academic Radiology. 10:673-684
Rationale and Objectives To aid in surgical and radiation therapy planning for prostate adenocarcinoma, a general-purpose automatic registration method that is based on mutual information was used to align magnetic resonance (MR) images and single ph
Autor:
Timothy J. Kinsella, Edward Kim, S. A. M. Beddar, John P. Spirnak, Rodney J. Ellis, D. Bruce Sodee, Ridgely Conant, Kurt H. Dinchman, Barry W. Wessels, Martin I. Resnick
Publikováno v:
International Journal of Radiation Oncology*Biology*Physics. 49:1281-1286
Purpose: We have previously presented a technique that fuses ProstaScint and pelvic CT images for the purpose of designing brachytherapy that targets areas at high risk for treatment failure. We now correlate areas of increased intensity seen on Pros
Autor:
Robert Stonecipher, D. Bruce Sodee, Errol M. Bellon, Dawn M. Martanovic, Clifford Riester, Wayne F. Poole, Michael A. Samuels, Rodney J. Ellis, J. Patrick Spirnak
Publikováno v:
The Prostate. 37:140-148
BACKGROUND ProstaScint® (Cytogen Corporation, Princeton, NJ) murine monoclonal antibody imaging is FDA-approved for imaging of prostate cancer patients at high risk for metastatic disease and patients postprostatectomy with a rising serum prostate-s
Publikováno v:
Seminars in nuclear medicine. 37(1)
The rationale on which positron emission tomography/computed tomography (PET/CT) imaging is based, combining the functional features of PET with the anatomic detail of CT, provides many advantages that are easily transferable to single-photon emissio
Publikováno v:
The Journal of urology. 175(5)
We determined the prognostic role, if any, of the ProstaScint (111)indium-capromab pendetide scan before salvage radiotherapy for biochemical recurrence after RP for localized prostate cancer.We reviewed the records of 649 patients who underwent a Pr
Autor:
Peter Faulhaber, Gregory T. MacLennan, Martin I. Resnick, George Bakale, D. Bruce Sodee, A. Dennis Nelson
Publikováno v:
Clinical prostate cancer. 3(4)
The primary objective of this overview is to apprise clinical urologists and oncologists of the current state of fused multimodality imaging of prostate cancer, which can be applied to optimize treatment by ensuring that a patient's disease is charac
Publikováno v:
Academic radiology. 12(7)
Three-dimensional (3D) nonrigid image registration for potential applications in prostate cancer treatment and interventional magnetic resonance (iMRI) imaging-guided therapies were investigated.An almost fully automated 3D nonrigid registration algo
Autor:
Timothy J. Kinsella, John P. Spirnak, Kurt H. Dinchman, Rodney J. Ellis, D. Bruce Sodee, Michael A. Samuels, Andrew W O’Leary, Martin I. Resnick
Publikováno v:
International journal of radiation oncology, biology, physics. 48(3)
Purpose: We present a technique that fuses pelvic CT scans and ProstaScint images to localize areas of disease within the prostate gland to customize prostate implants. Additionally, the acute toxicity results from the first 43 patients treated with